Klaus
Elenius
Professor, Institute of Biomedicine
Director, BioCity Turku
Turku Bioscience Centre
MD, PhD, professor
Research
ACTIONABLE RECEPTOR TYROSINE KINASE SIGNALING
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
Current topics
- Screens for predictive RTK mutations
- Novel RTK signaling mechanisms
- Development of preclinical models for development novel RTK inhibitors
- Sequencing of RTK inhibitor drug administration with cytotoxic agents
- In vitro “basket trials” with ErbB inhibitor drugs
- RTK signaling in angiogenesis and cardiovascular diseases
- RTKs in pediatric malignancies
- Biological role of novel ErbB4 isoforms in diseases and development
Elenius Lab members
- Anne Jokilammi, PhD
- Elli Narvi, PhD
- Deepankar Chakroborty, MSc
- Juho Heliste, MD
- Marika Koivu, MSc
- Johannes Merilahti, MSc
- Veera Ojala, MSc
- Janne Nordberg, MD
- Fred Saarinen, MSc
- Katri Vaparanta, MSc
- Kaisa Aalto, BM
- Maria Helkkula, BM
- Matias Mäenpää, BM
- Peppi Kirjalainen, BM
- Jori Torkkila, BM
Publications
Genome-wide screen of gamma-secretase-mediated intramembrane cleavage of receptor tyrosine kinases (2017)
Molecular Biology of the Cell
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase (2017)
Journal of Biological Chemistry
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Human Metaplastic Breast Carcinoma and Decorin (2017)
Cancer Microenvironment
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Farmakogenetiikka saapuu klinikkaan (2016)
Duodecim
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Activating ERBB4 mutations in non-small cell lung cancer (2016)
Oncogene
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Novel Targets for the Treatment of Ameloblastoma (2015)
Journal of Dental Research
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer (2014)
PLoS ONE
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Hypoxia-inducible Factor-1α Induces ErbB4 Signaling in the Differentiating Mammary Gland (2014)
Journal of Biological Chemistry
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
ErbB4, a receptor tyrosine kinase, coordinates organization of the seminiferous tubules in the developing testis. (2014)
Molecular Endocrinology -Baltimore-
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
High frequency of BRAF V600E mutations in ameloblastoma (2014)
Journal of Pathology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))